Published On: Mon, May 10th, 2021

Sun Pharma signs licensing deal with Lilly for Covid-19 drug baricitinib

Tagged with: | | | | | | | |

Sun Pharmaceutical Industries () said that it has signed a royalty-free, non-exclusive voluntary licensing agreement with for expanding access to the latter’s baricitinib in India.

The Indian pharma company Sun Pharma will manufacture and distribute baricitinib in India.

Baricitinib has been granted restricted emergency use by India’s Central Standard Control Organization (CDSCO) in combination with remdesivir for the of suspected or lab confirmed Covid-19 in hospitalized adults needing supplemental oxygen, extracorporeal membrane oxygenation (ECMO), or invasive mechanical ventilation.

Sun Pharma signs licensing deal with Lilly for Covid-19 drug baricitinib

Sun Pharma signs licensing deal with Lilly for Covid-19 drug baricitinib. Image courtesy of visuals3Dde from Pixabay.

– CEO of Sun Pharma India business said: “Through this collaboration, we aim to join our forces with Lilly to accelerate access to baricitinib in India at a time when it is most needed. This is another step by Sun Pharma towards making more treatment options available to patients in India for dealing with the pandemic.”

Related posts

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>